​

Introduction

For Triple Negative Breast Cancers (TNBC) there are no effective specific targeted therapy readily available. CD44 is found overexpressed in many tumours, in particular TNBC, making this an attractive receptor for therapeutic targeting. Besides, Hsp90 inhibitors (Hsp90i) have been shown as promising molecules to treat cancer. Here we show our both drug delivery approaches to target TNBC. First, we describe a unique non-cationic liposome-based siRNA delivery system with a core composed of siRNA:protamine complexes and a shell designed for the active targeting of CD44-expressing cells using for the first time an anti-CD44 aptamer as targeting ligand. This was evaluated for the silencing of the luciferase reporter gene (luc2) in a TNBC breast cancer model in vitro and in vivo (orthotopically implanted) (Alshaer, 2015, 2018). Secondly, we succeeded to use the inhibition of the chaperone Hsp90 ​